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THERE IS GROWING AWARENESS that a potent inhibitor of nitric oxide (NO) synthases (NOS), namely, asymmetric dimethylarginine (ADMA), is accumulated in diverse diseases associated with accelerated atherosclerosis (1, 3, 6, 7, 13, 21, 45, 56) . The plasma levels of ADMA are ϳ1 mol/l in healthy humans and are elevated more than twofold in hypercholesterolemic individuals (3, 5, 56) . In elderly patients with peripheral arterial disease and generalized atherosclerosis, plasma ADMA levels range from 2.5 to 3.5 mol/l and correlate with the severity of vascular disease (2, 3, 5, 27) . In patients with chronic renal failure, which is a condition associated with an ϳ20-fold increase in risk for fatal cardiovascular complications, plasma ADMA levels may be elevated ninefold (5, 16, 28, 29, 43, 46, 53, 57) . Interestingly, it was recently demonstrated that yet another inhibitor of NOS, phenylacetic acid (PAA), which is a degradation product of phenylalanine, accumulates in plasma of patients with end-stage renal failure (22) . Collectively, these data indicate that the activity of NOS in these patients may be significantly suppressed. Although there is a certain amount of direct evidence to support the presence of stimulated expression of inducible NOS (iNOS) in atherosclerosis, which is associated with foam cells (20, 23, 33, 34) , no study has confirmed the roles of elevated ADMA levels or NO deficiency in foam cell formation and modified LDL uptake by macrophages during chronic renal failure.
Foam cell formation occurs as a result of unregulated uptake of modified lipoproteins by scavenger receptors with deposition of cholesterol esters in the cytoplasm (38, 42, 55) . The emerging concept that the lectin-like, oxidized, low-density lipoprotein receptor (LOX-1), which is the major scavenger receptor for oxidized LDL (OxLDL) in endothelial cells (54) , plays an important role in the development of endothelial dysfunction and early atherogenesis is the subject of considerable interest (11) . This hypothesis is based on several key findings as follows: 1) upregulation of LOX-1 and uptake of OxLDL suppresses NO production by endothelial cells (12) , 2) upregulation of LOX-1 increases adhesion of monocytes to the endothelium under static and flow conditions (18) , and 3) LOX-1 is upregulated in activated macrophages and is abundant in atherosclerotic plaques (41) . These findings suggest the potential involvement of LOX-1 in foam cell formation (41) . The possibility of an existing synergism between upregulated LOX-1 and defective NO synthesis in activated macrophages, although highly plausible, has not been explored. Our findings demonstrate that inhibition of NO synthesis by elevated ADMA levels in activated macrophages leads to upregulation of LOX-1, which is associated with increased uptake of oxidized LDL and rapid formation of lipid-laden cells.
MATERIALS AND METHODS
Cell culture. Suspensions of human monocytic leukemia HL-60 cells were maintained in RPMI 1640 medium that contained 20% fetal bovine serum. Differentiation of HL-60 cells into monocytes/macrophages was stimulated with 10 nM PMA for 4 -5 days. ADMA or N G -nitro-L-arginine methyl ester (L-NAME) was added to the cell culture medium for 24 -48 h before experiments were performed.
Western blotting. Cells were lysed in ice-cold lysis buffer that contained the following: 20 mM Tris ⅐ HCl, 140 mM NaCl, 1 mM EDTA, complete miniprotease inhibitor cocktail, 1% Triton X-100, 0.1% SDS, 1% sodium deoxycholate, 1 mM NaF, and 1 mM orthovanadate, pH 7.8. Protein concentration of the lysates was determined with Pierce bicinchoninic protein assay against BSA standards. The samples were diluted with SDS sample buffer and stored at Ϫ20°C. Total cellular protein (20 g) was separated in a 4 -20% Tris-glycine gel (Invitrogen) and electroblotted to Immobilon-P membranes (Millipore). The membranes were blocked with 4% BSA in PBS for 1 h, incubated with primary antibodies for 1 h [1:1,000 dilutions of mouse monoclonal LOX-1 antibody and mouse monoclonal ␤-tubulin antibody (Sigma)], and incubated with horseradish peroxidase-conjugated goat anti-mouse antibody (Amersham) for 30 min. The membranes were then washed three times with 0.1% Tween 20 in PBS, pH 7.4, for 5 min each, and protein-antibody conjugates were detected by chemiluminescence (Super Signal CL-HRP; Pierce Chemical).
Fluorescence-activated cell sorting analysis and NO production measurement. NO production was measured using fluorescence-activated cell sorting (FACS) analysis in HL-60 cells loaded with the NO-sensitive fluorescent dye 4-amino-5-methylamino-2Ј,7Ј-difluorofluorescein diacetate (DAF-FM diacetate). Suspensions of HL-60 cells were maintained in RPMI 1640 medium that contained 20% fetal bovine serum. Differentiation of HL-60 cells into monocytes/macrophages was stimulated with 10 nM PMA for 4 days. ADMA or L-NAME was added to the cell culture medium for 24 h before experiments were performed. Fluorescence labeling of PMA-differentiated HL-60 cells was accomplished by incubation with 1 nM DAF-FM diacetate for 45 min (30, 36) . Cells were washed three times by centrifugation at 1,500 rpm. L-NAME (300 M) or ADMA (15 M) was added in the washing buffer. We analyzed 10,000 cells/ sample using a Becton-Dickinson FACSCalibur cytometer equipped with a 488-nm laser. Emitted light was measured in control and treated cells. Signal overlap between the fluorescence 1 (DAF-FM) and fluorescence 2 (phycoerythrin) channels was compensated for appropriately. Data were expressed as arbitrary fluorescence units, and histograms were plotted using CELLQuest software (BectonDickinson).
RNA interference and in vitro small interfering RNA transfection. Small interfering RNA (siRNA) sequences targeting the OLR1 gene (National Center for Biotechnology Information accession number NM_002543) were synthesized by researchers at Dharmacon Research (Lafayette, CO) using SMART selection. HL-60 cells were transfected with siRNAs using the GeneSilencer siRNA transfection protocol (Gene Therapy Systems). Four days before transfection, HL-60 cells were treated with 10 nM PMA and then plated on polylysine-coated coverslips 1 day before transfection; this insured that the cells were 50 -70% confluent on the day of transfection. The GeneSilencer reagent was diluted in serum-free RPMI medium according to the manufacturer's (Gene Therapy Systems) protocol. HL-60 cells were transfected with siRNAs at a concentration of 0.25 M. Control cells were incubated with RPMI alone without siRNA or with and without GeneSilencer reagent. The siRNA-GeneSilencer mixture was added to cells growing in serum-free RPMI, and cells were incubated at 37°C for 72 h. L-NAME and ADMA were added to the culture medium of growing cells after 48 h of incubation with siRNA. Cells were harvested 72 h after transfection for protein expression or were studied using fluorescence microscopy.
Lipoprotein modification and labeling. LDL was oxidized by incubating 200 g/ml LDL in PBS that contained 5 mol/l CuSO4 at 37°C for 27 h (44). This procedure resulted in an electrophoretic mobility for oxidized LDL of 1.0 relative to albumin and of 4.0 relative to native LDL (44) . Fluorescent labeling of LDL was performed by adding 75 l of 3 mg/ml 1,1Ј-dioctadecyl-3,3,3Ј,3Ј-tetramethylindocarbocyanine perchlorate (DiI) in dimethyl sulfoxide to 4 mg (protein) of oxidized LDL. The mixture was incubated under sterile conditions at 37°C for 8 h. Labeled lipoproteins were isolated by ultracentrifugation (100,000 g for 4 h). This procedure typically resulted in incorporation of 5-15 g of DiI per milligram of LDL protein.
DiI-OxLDL uptake assays. Uptake of DiI-OxLDL was used to assess the functional consequences of upregulated LOX-1 expression. HL-60 cells were cultured on polylysine-coated sterile coverslips. The siRNA-transfected and -nontransfected, primed HL-60 cells were treated with the indicated concentrations of ADMA or L-NAME in serum that contained RPMI for 24 h. Cells were then washed, fluorescent lipoprotein (DiI-OxLDL, 10 g/ml) was added, and incubation continued for 24 h in the serum-containing medium. HL-60 cells were washed with ice-cold phosphate-buffered saline (PBS, pH 7.4) and immediately fixed with 4% paraformaldehyde. Cells were examined using fluorescence microscopy (Nikon Diaphot) and image analysis (Universal Imaging). Data are expressed as fluorescence intensity (in arbitrary units) of DiI-OxLDL.
Oil-red O staining. The siRNA-transfected and -nontransfected HL-60 cells were cultured on polylysine-coated glass coverslips, and cells were treated with 300 M L-NAME and 15 M ADMA for 24 h. The cells were washed three times with PBS, fixed with 4% paraformaldehyde, and stained with oil-red O and hematoxylin as previously described (25, 37) .
RESULTS

Induction of LOX-1 protein expression by ADMA and L-NAME in HL-60 cells.
We modeled the specific effects of NO deficiency on LOX-1 expression in HL-60 cells by exposing the cells to NOS inhibitors. HL-60 cells were cultured for 4 days in the presence of 10 nM PMA and were then treated with different concentrations of L-NAME or ADMA for an additional 24 h before protein isolation. Using Western blot analysis, we found that 15 M ADMA and 300 M L-NAME maximally induced LOX-1 gene expression in PMA-differentiated HL-60 cells (Fig. 1) . LOX-1 protein expression was increased by 25% in control PMA-differentiated HL-60 cells compared with undifferentiated cells and showed robust increases of ϳ217% after exposure to 15 M ADMA and ϳ138% after exposure to 300 M L-NAME (Fig. 1) . Immunodetectable iNOS was faintly detectable in nonprimed HL-60 cells but was readily detectable in PMA-differentiated HL-60 cells. Treatment with L-NAME or ADMA did not modify iNOS expression in PMA-differentiated macrophages within the time frame of these experiments (Fig. 1) .
Inhibition of NO production by L-NAME and ADMA in HL-60 cells. To elucidate whether the above maximally effective (in LOX-1 expression) concentrations of L-NAME and ADMA were indeed associated with suppression of NO production, we used FACS analysis of cells loaded with the NO-sensitive fluorescent indicator DAF-FM diacetate. DAF-FM diacetate-loaded HL-60 cells were pretreated with PMA to induce iNOS and were either treated or were not treated with 300 M L-NAME or 15 M ADMA for 24 h before the experiments were performed (Fig. 2, C and D) . We found a robust increase in NO production in PMA-differentiated HL-60 cells compared with nondifferentiated HL-60 cells (Fig. 2, A and B) . Pretreatment with 300 M L-NAME or 15 M ADMA was associated with a profound suppression of NO production in a subpopulation of macrophages that expressed the highest iNOS activity (Fig. 2, C and D) . These differences in NO generation between primed HL-60 cells exposed and not exposed to NOS inhibitors were compared using KolmogorovSmirnov analysis and were found to be statistically significant (P Ͻ 0.001). On the other hand, despite the 20-fold difference in the concentrations of L-NAME and ADMA, the extent of iNOS suppression appeared to be comparable. This is surprising, because L-NAME has a much more potent inhibitory effect on the isolated enzyme in vitro. However, in in vivo systems, (4) demonstrated that in cholesterol-fed rabbits, administration of L-NAME "did not induce a further significant increase in intima/media ratio as compared to the cholesterol group. Intima/media ratios were significantly correlated to the ADMA levels in individual rabbits." These data clearly indicate that ADMA (even at concentration of 2.2 uM) exerted a proatherogenic effect over and above that of cholesterol feeding, whereas administration of L-NAME did not. One of the peculiarities of in vivo action of these two inhibitors is related to their discrepant effects on the yϩ carrier and intracellular L-arginine import. Closs et al. (9) demonstrated that ADMA potently suppresses the yϩ transporter, whereas L-NAME does not (9) . This implies that in activated macrophages with already-enhanced L-arginine utilization, inhibition of its import by ADMA could have an additive effect. Indeed, Chan et al. (10) showed that the end effect of ADMA is enhanced twofold in the presence of reduced L-arginine concentration (10). The above scenario may provide a plausible explanation of our findings. Although the concentration of ADMA employed in our experiments was quite high, it was within the pathophysiologically relevant range. According to Boger et al. (4 -6) , ADMA levels can be increased up to 10-fold in the serum of patients with chronic renal failure.
Specific inhibition of LOX-1 protein expression by siRNAs. To determine the effects of siRNA on LOX-1 expression levels, ADMA-or L-NAME-treated and -untreated primed HL-60 cells were examined by Western blot analysis. Treatment of HL-60 cells with siRNA produced a marginal decrease in LOX-1 expression in nondifferentiated and differentiated cells but resulted in a threefold decrease in LOX-1 expression in L-NAME-and ADMA-treated differentiated HL-60 cells as judged from the results of Western blot analysis (Fig. 3) . C, E , and G) HL-60 cells were incubated for 24 h at 37°C with 10 g/ml OxLDL. Cells were then washed, fixed, and examined with a ϫ60 objective using phase-contrast or a fluorescein filter set.
Uptake of OxLDL by ADMA-or L-NAME-treated HL-60 cells.
To determine whether upregulated expression of LOX-1 by ADMA and L-NAME is correlated with enhanced uptake of OxLDL, DiI-labeled OxLDL internalization into HL-60 cells was measured in siRNA-transfected and -nontransfected cells. HL-60 cells were cultured in the presence of L-NAME or ADMA for 24 h before incubation with the fluorescent LOX-1 ligand DiI-OxLDL for 24 h in serum-containing medium. Unbound ligand was removed by repeated washings, cells were fixed with 4% paraformaldehyde, and the amount of ligand associated with cells was determined. As shown in Fig. 4 , treatment of HL-60 cells with L-NAME or ADMA substantially induced DiI-OxLDL uptake with HL-60 cells. This effect of ADMA on OxLDL was maximal at a concentration of 15 M (2.45-fold increase compared with control; P Ͻ 0.001). L-NAME (300 M) resulted in a 2.36-fold (P Ͻ 0.001) increase in fluorescence intensity compared with control (Figs.  4 and 5) . The DiI-OxLDL accumulation was decreased by LOX-1-directed siRNA by 2.6-fold (P Ͻ 0.01) in L-NAMEtreated and 3.8-fold (P Ͻ 0.001) in ADMA-treated HL-60 cells (Fig. 5) . Furthermore, DiI-OxLDL uptake was decreased by 2.4-fold in nonprimed compared with PMA-differentiated HL-60 cells and was downregulated by LOX-1-directed siRNA (Fig. 5) , which suggests that HL-60 cells exhibit a constitutive expression of LOX-1 that may be involved in the accumulation of modified LDL even under basal conditions (see Figs. 4 and 5) .
Effects of L-NAME and ADMA on LOX-1-receptor expression and foam cell formation in HL-60 macrophages.
To examine the effects of L-NAME and ADMA on the transformation of PMA-treated HL-60 macrophages into foam cells, staining with oil-red O was performed. Oil-red O staining showed that the stimulatory effects of L-NAME and ADMA on LOX-1 expression were accompanied by the appearance of accumulation of intracellular lipid droplets typical of foam cell formation (Figs. 6 and 7) . Oil-red O staining was decreased 1.6-fold by LOX-1-directed siRNA in unactivated HL-60 cells (Fig. 7) , which suggests that HL-60 cells express LOX-1 constitutively. After L-NAME treatment, the intensity of oilred O staining was increased 2.8-fold (P Ͻ 0.001) and was suppressed 2.2-fold (P Ͻ 0.001) by LOX-1-directed siRNA (see Fig. 6 ). ADMA resulted in a 1.9-fold (P Ͻ 0.001) increase in oil-red O staining, and this effect was suppressed by LOX-1-directed siRNA (see Figs. 6 and 7) .
Inhibitory effects of NO donors and SOD mimetics on upregulated LOX-1 protein expression in L-NAME-or ADMAtreated human umbilical vein endothelial cells.
To dissect the roles of NO deficiency and/or excessive generation of reactive oxygen species (ROS), both of which are associated with inhibition of iNOS by ADMA or L-NAME, in the induction of LOX-1 expression in PMA-differentiated HL-60 cells, cells were supplemented with 100 M of the NO donor N-hydroxy-L-arginine (NOHA) and/or 2.5 M of the SOD mimetic Mn(II-I)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP) for 24 h during the standard incubation with 300 M L-NAME or 15 M ADMA. In addition, differentiated HL-60 cells were also subjected to 100 M L-arginine. Cell lysates were examined by Western blot analysis using anti-LOX-1 antibody. As expected, treatment with either L-NAME or ADMA increased LOX-1 expression (Fig. 8) . Pretreatment of these cells with 2.5 M MnTBAP or 100 M NOHA significantly suppressed LOX-1 upregulation in L-NAME-and ADMA-exposed cells (Fig. 8) . No additive effects of pretreatment by NOHA and MnTBAP were observed in L-NAME-exposed HL-60 cells, whereas an additive effect was found in ADMA-treated cells, which suggests that both nitrosative and oxidative stresses are responsible for LOX-1 expression in ADMA-treated PMAdifferentiated HL-60 cells (Fig. 9) . Intriguingly, treatment with L-arginine also inhibited LOX-1, which suggests that the substrate deficiency may be in part responsible for the sustained decrease in NO synthesis in activated macrophages (see Fig. 8 ).
DISCUSSION
This work shows for the first time that the NOS inhibitors ADMA and L-NAME increase the abundance of LOX-1, the dominant endothelial scavenger receptor for OxLDL, and lead to accumulation of OxLDL and foam cell formation in PMAprimed HL-60 cells. Previously it was demonstrated that circulating human blood monocytes or undifferentiated THP-1 cells express only trace levels of LOX-1 transcripts and protein, but LOX-1 was upregulated together with other scavenger receptors in both cell types after differentiation (26, 41, 50) . In THP-1 cells, LOX-1 mRNA expression was time-and dosedependently induced as early as 12 h after treatment with 10 nM PMA and remained elevated for at least 7 days (41). Interestingly, these results appear to correlate with previous reports that scavenger receptor A (SR-A) displays time-and concentration-dependent induction in PMA-treated THP-1 cells (15) . In addition, expression of LOX-1 mRNA was significantly upregulated in a time-and concentration-dependent manner by the inflammatory cytokine TNF-␣ in murine peritoneal macrophages (50). Our results strongly indicate that the nonprimed human monocytic leukemia cell line HL-60 is characterized by the constitutive expression of LOX-1 that can mediate basal scavenging of modified LDL by these cells. The LOX-1 protein expression increased by 25% in PMA-differentiated HL-60 cells compared with undifferentiated monocytic cells. After 24 h of exposure to ADMA, LOX-1 showed a robust increase of ϳ217% in PMA-differentiated HL-60 cells and ϳ138% after 24 h of exposure of L-NAME of differentiated cells compared with control cells. In addition, upregulation of LOX-1 was associated with a greater than twofold increased accumulation of DiI-OxLDL in macrophages subjected to ADMA or L-NAME compared with untreated differentiated HL-60 cells. LOX-1-directed siRNA decreased by two-to threefold the uptake of DiI-OxLDL under these conditions. Thus the finding of ADMA-induced upregulation of LOX-1 in macrophages implicates this circulating NOS inhibitor, which is consistently elevated in diverse cardiovascular diseases and chronic renal failure, in the progression of atherosclerosis.
The appearance of lipid-laden foam cells is one of the hallmarks of fatty streaks and atherosclerotic plaques. The transformation of macrophages into lipid-laden foam cells is most likely the result of receptor-mediated uptake of cholesterol-rich particles. Several mechanisms are known to contribute to the monocyte scavenging of OxLDL (60) . Monocytes and macrophages possess receptors for OxLDL including SR-A (the first OxLDL receptor to be characterized and cloned; Ref. 35) , scavenger receptors BI, CD36, CD68, and LOX-1, and the scavenger receptor for phosphatidylserine and oxidized lipoprotein (3, 14, 24, 40, 52) . Therefore, macrophage transformation into the foam cell can potentially be governed by several lipoprotein receptors that mediate the uptake of cholesterol-rich particles (14, 41) . The contribution of LOX-1 to this process remains uncertain. Our results indicate that blockade of the iNOS synthesis of NO by activated macrophages rendered macrophages with a foamy appearance as detected with oil-red O lipid staining: ADMA or L-NAME increased oil-red O staining 1.9-and 2.8-fold, respectively. The siRNA duplex-mediated LOX-1 gene silencing decreased approximately twofold the oil-red O staining of activated macrophages, which suggests that LOX-1 is predominantly involved in the regulation of the foamy appearance by macrophages. These findings provide direct evidence that LOX-1 is a specific receptor for OxLDL, which plays a critical role in foam cell formation especially when iNOS is inhibited.
LOX-1 was originally purified as a receptor for OxLDL (11, 44) and is highly expressed by vascular endothelial cells, macrophages, and vascular smooth muscle cells in atherosclerotic lesions at various stages in humans and rabbits (31, 32, 40, 47, 50, 51) . LOX-1 is a type II membrane glycoprotein with an extracellular COOH-terminal lectin domain that is initially synthesized as a 40-kDa precursor protein with an N-linked high-mannose-type carbohydrate and is further glycosylated and processed into a 50-kDa mature form (11, 51) . Importantly, the LOX-1 gene is a so-called immediate early gene that possess NF-B response element (54) and is dynamically modulated by TNF-␣ (50), transforming growth factor-␤ (15), angiotensin II (49), endothelin-1 (49), peroxisome proliferatoractivated receptor-␣ (8), oxidized LDL and phorbol esters in vitro (11, 41) , and proinflammatory conditions, oxidative stress, and hemodynamic abnormalities in vivo (11) . The precise mechanism(s) by which increased ADMA level and reduced NO production induce the foamy appearance of macrophages remains unknown. It is well established, however, that NO may act as an antiatherogenic molecule (12, 19, 22, 39) . Reduced NO availability was shown to be associated with increased oxidative stress in endothelial cells (12) and to in turn activate the transcription factor NF-B (12, 48) and lead to enhanced endothelial adhesiveness associated with expression of vascular cell adhesion molecule-1 and monocyte chemotactic protein-1 (12, 48) . Present data extend this view of an antiatherogenic effect of NO on macrophages: LOX-1 is upregulated under conditions when NO production is reduced. It was previously demonstrated that binding of OxLDL to LOX-1 results in a significant increase in the generation of ROS by endothelial cells (12) . The increased binding of OxLDL to LOX-1 and ROS production could facilitate the oxidation of native LDL or partially oxidized LDL accumulated via other scavenger receptors and could in turn upregulate LOX-1 expression (12, 48) and contribute to further accumulation of Ox-LDL, O 2 Ϫ ⅐ generation, and peroxynitrite formation. Using an NO donor and a SOD mimetic, we attempted to prevent the induction of LOX-1 expression by differentiated HL-60. The SOD mimetic and NO donor significantly suppressed LOX-1 upregulation in L-NAME-and ADMA-treated macrophages (see Fig. 8 ). No additive effect of pretreatment by the SOD mimetic was observed in L-NAME-exposed differentiated HL-60 cells, whereas an additive effect was found in ADMA-treated cells; this suggests that both nitrosative and oxidative stresses are responsible for LOX-1 expression in ADMA-treated differentiated HL-60 cells. The possibility for the development of substrate deficiency in activated macro- corresponding control PMA-differentiated nontransfected cells and L-NAMEor ADMA-treated differentiated nontransfected cells; ***P Ͻ 0.001 vs. corresponding nontransfected differentiated and transfected differentiated HL-60 cells. Fig. 8 . Effects of NO donor and SOD mimetic on LOX-1 expression in L-NAME-or ADMA-treated HL-60 cells. Cells were treated with 300 M L-NAME or 15 M ADMA and/or were supplemented with NO donor N-hydroxy-L-arginine (NOHA) and/or SOD mimetic Mn(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP) for 24 h, and lysates were blotted with LOX-1 antibody. Treatment with either L-NAME or ADMA resulted in the upregulation of LOX-1 expression. MnTBAP alone significantly suppressed the LOX-1 upregulation in ADMA-treated HL-60 cells, whereas NOHA downregulated the LOX-1 upregulation in L-NAME-exposed cells. No additive effect was afforded by NOHA in L-NAME-exposed HL-60 cells, but an additive effect was found in ADMA-exposed HL-60 cells. Fig. 9 . Hypothetical summary of L-NAME-and ADMA-induced upregulation of LOX-1 in macrophages through deficient NO production vis a vis oxidative and nitrosative stress pathways.
phages is supported by the finding that L-arginine partially prevented LOX-1 overexpression in activated HL-60 cells. Our hypothesis on the mechanisms of LOX-1 induction in macrophages exposed to iNOS inhibition is summarized in Fig. 9 .
NO has been shown to have both preventive and promotional effects on cell demise by either turning on apoptotic pathways or inhibiting several components of the proapoptotic cascade (17, 19, 58, 59) . NO causes a G 1 cell cycle arrest in tight correlation with p53 expression, transactivation, and subsequent upregulation of p21
Waf1/Cip1 (58) . Interestingly, expression of p21
Waf1/Cip1 may prevent initiation of apoptosis at relatively low concentrations of NO. At high concentrations of NO, the activation of proapoptotic signaling systems such as p53 accumulation, opening of permeability transition pores, and cytochrome c leakage into the cytoplasm activate caspases and set in motion the NO-mediated apoptotic cell death (58) . In macrophages, the consensus is that iNOS induction promotes cell apoptosis (17, 58) . It is tempting to speculate that our findings of accumulated foam cell formation in ADMA-and L-NAME-exposed macrophages is consistent with the scenario that iNOS inhibition could prevent the apoptotic clearance of lipid-laden macrophages. In summary, our data offer an additional putative mechanism for ADMA-induced accelerated atherosclerosis in patients with chronic renal failure, namely, via induction of LOX-1 expression and increased OxLDL uptake by macrophages. Together with previous demonstrations that OxLDL uptake leads to increased synthesis of ADMA that affects endothelial cell-monocyte interactions, the data suggest the existence of a vicious circle from inhibition of NO production and subsequent increase in OxLDL accumulation and further increases in the synthesis of the NOS inhibitor ADMA, which then accelerates foam cell formation. The data illustrate an additional nonendothelial mode of the antiatherogenic action of NO: prevention of LOX-1 induction and lipid accumulation in macrophages.
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